Incivek FDA Approval History

FDA Approved: Yes (Discontinued) (First approved May 23, 2011)
Brand name: Incivek
Generic name: telaprevir
Dosage form: Tablets
Company: Vertex Pharmaceuticals Incorporated
Treatment for: Hepatitis C

Marketing Status: Discontinued

Incivek (telaprevir) is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated, in combination with peginterferon alfa and ribavirin, for the treatment of chronic hepatitis C (CHC).

Development timeline for Incivek

Date	Article
May 23, 2011	Approval FDA Approves Incivek (telaprevir) for People with Hepatitis C
Apr 29, 2011	FDA Advisory Committee Unanimously Recommends Approval of Telaprevir for People with Hepatitis C
Jan 20, 2011	U.S. FDA and Health Canada Grant Priority Reviews for Telaprevir for the Treatment of Hepatitis C
Nov 23, 2010	Vertex Completes New Drug Application for Telaprevir for Hepatitis C

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Drug Status

Availability Discontinued

Pregnancy & Lactation Risk data available

CSA Schedule* Not a controlled drug N/A

Approval History Drug history at FDA

Incivek FDA Approval History

Development timeline for Incivek

See also

Further information